4 - oxo - Derivatives of 1, 3, 8 - triaza 4.5 Deans as inhibitors of Potassium Channel Kv1.5, a composition that includes and its use in the treatment of heart disease.

摘要

Derivatives of 4 - oxo - 1,3,8 triaza - spiro [4,5] Deans which are useful as inhibitors of 1.5 kV Potassium Channel activity and that provide for atrial Selective antiarrhythmic. Compositions and their use for treating atrial antiarritmia - selective.Claim 1: a compound having the formula (1), in which R is optionally substituted phenyl optionally substituted phenyl; r1 is alkyl; R2 is C1 - 6 linear or branched optionally substituted cycloalkyl, optionally substituted C3 - 6 or - C (o) R23,Where R23 is C1 - 6 linear or branched alkyl, optionally substituted cycloalkyl or C3 6 optionally substituted; R3 is Hydrogen; select between: 1) 2) C1 - 6 linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted or C3 - 6; 3) - C (o) where alkyl R4, R4 is C1 - 6 Linear or branched optionally substituted cycloalkyl, optionally substituted C3 6,Optionally substituted heterocycle.Optionally substituted aryl or heteroaryl optionally substituted; 4) - C (o) where each nr5r6 R5 and R6 is selected regardless of: a) b) hydrogen; C1 - 6 linear or branched alkyl, optionally substituted cycloalkyl C3 - 7; c) optionally substituted; (d) - or7; R7 is Hydr Ogeno or C1 - 6 linear or branched alkyl, optionally substituted; e) nr8r9; where each R8 andR9 is independently Hydrogen, C1 - 6 linear or branched alkyl, optionally substituted C1 - 6 linear or branched alkoxy optionally substituted,- or Oh - co2r10; where R10 is C1 - 6 linear or branched alkyl, optionally substituted; or R8 and R9 can be taken together with e! Carbon Atom to which they are United to form a Ring optionally substituted has 3 to 7 Atoms in the ring and optionally containing one or more heteroatoms in the Ring selected independently among nO or s; or (f) R5 and R6 can be taken together with the carbon Atom to which they are United to form a Ring optionally substituted has 3 to 7 Atoms in the ring and optionally containing one or more heteroatoms in the Ring selected regardless of N, or S; 5) - C (R12, nr11)Where r11es to hydrogen); (b) C1 - 6 linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted or C3 - 6; (c) - (d); or - ns; and R12) is a linear or branched alkyl C1 - 6 or optionally substituted cycloalkyl, optionally substituted C3 - 6; (b) - OR13, where R13 is Hydrogen C1 - 6, linear or branched alkyl, optionally substituted,C3 - optionally substituted cycloalkyl optionally substituted aryl or 6; or c) where each nr14r15 R14 and R15 is independently Hydrogen, optionally substituted aryl, alkyl C1 - 6 linear or branched or optionally substituted cycloalkyl, optionally substituted C3 - 8; 6) - so2r16; Donde R16 is optionally substituted aryl,C1 - 6 linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted or C3 - 6; 7) - C (o) R17, where aryl or heteroaryl R17 is optionally substituted or optionally substituted; 8) - C (o) or18; where R18 is C1 - 6 linear or branched alkyl, optionally substituted, cicloalqui The C3 - 6 optionally substituted aryl or optionally substituted; L, L1 and L2 are units of Union,Each independently is a unit that has the formula: - [C (R19) 2] n -, in which each R19, in each case, Selected independently from Hydrogen, Methyl or Ethyl, N is 1 to 4; and each of X, y and Z is independently 0 OR 1; or a Pharmaceutical Salt form to Number of the same.